As per the research report, the size of the Europe Enteral Feeding Devices Market has been forecasted at USD 1.51 billion in 2021 and estimated to be growing at a CAGR of 7.6%, to worth USD 2.17 billion by 2026. A growing number of hospitals and ambulatory care services embrace enteral nutrition as an effective system of clinical nutrition.
Enteral nutrition generally refers to any feeding method that uses the gastrointestinal (GI) tract to deliver part or all of a person's caloric requirements. It can include a normal oral diet, the use of liquid supplements, or delivery of part or all of the daily requirements by use of a tube (tube feeding).
Rising incidences of chronic diseases and disorders, rapidly growing geriatric population, increasing healthcare expenditure, rising prevalence of preterm births, and increasing demand for home care are the European Enteral Feeding Market drivers. Complications associated with enteral nutrition, patient safety risks, and the occurrence of feeding and medication errors are expected to confine the growth of the enteral feeding formulas market.
This research report on the European Enteral Feeding Formulas Market has been segmented and sub-segmented into the following categories:
By Product:
By Stage:
By Application:
By End User:
By Country:
The oncology application segment held the largest share of the enteral feeding formulas market in 2019, primarily due to the high prevalence of malnutrition among cancer patients.
Key players operating in the European Enteral Feeding Formulas Market profiled in this report are Abbott Laboratories (U.S.), Nestlé S.A. (Switzerland), Danone S.A. (France), Fresenius Kabi AG (Germany), Mead Johnson Nutrition Company (U.S.), B. Braun Melsungen AG (Germany), Hormel Foods, LLC (U.S.), Victus Inc. (U.S.), Meiji Holdings Co., Ltd. (Japan), and Global Health Product Inc. (U.S.).
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product
5.1.1 Polymeric
5.1.2 Monomeric
5.1.3 Disease-Specific Formulas
5.1.4 Y-o-Y Growth Analysis, By Product
5.1.5 Market Attractiveness Analysis, By Product
5.1.6 Market Share Analysis, By Product
5.2 Stage
5.2.1 Adults
5.2.2 Pediatrics
5.2.3 Y-o-Y Growth Analysis, By Stage
5.2.4 Market Attractiveness Analysis, By Stage
5.2.5 Market Share Analysis, By Stage
5.3 Application
5.3.1 Oncology
5.3.2 Gastroenterology
5.3.3 Neurology
5.3.4 Y-o-Y Growth Analysis, By Application
5.3.5 Market Attractiveness Analysis, By Application
5.3.6 Market Share Analysis, By Application
5.4 End Users
5.4.1 Hospitals
5.4.2 LTCS
5.4.3 Home Care
5.4.4 Y-o-Y Growth Analysis, By End Users
5.4.5 Market Attractiveness Analysis, By End Users
5.4.6 Market Share Analysis, By End Users
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By Type
6.1.3.4 By Application
6.1.3.5 By End Users
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product
6.1.4.3 By Stage
6.1.4.4 By Application
6.1.4.5 By End Users
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product
6.1.5.3 By Stage
6.1.5.4 By Application
6.1.5.5 By End Users
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Abbott Laboratories
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Nestle S.A.
8.3 Danone S.A.
8.4 Fresenius Kabi AG
8.5 Mead Johnson Nutrition Company
8.6 B. Braun Melsungen AG
8.7 Hormel Foods
8.8 LLC
8.9 Victus Inc.
8.10 Meiji Holdings Co. Ltd.
8.11 Global health Product Inc.
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
